Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Qilu Hospital of Shandong University: Clinical Trials & FDA Approval Profile

Qilu Hospital of Shandong University (Global / Institutional) sponsors 35 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 19 active protocols (11 recruiting now), 4 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)2.9%
Median Closed Enrollment vs National (145 pts)28 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Qilu Hospital of Shandong University
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)35
Active Pipeline (Recruiting Now)19 (11)
Completed vs Stopped Early4 / 1 (2.9%)
Median Closed Actual Enrollment28 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Qilu Hospital of Shandong University
Hospital Research SiteLocationShared Protocols
Qilu Hospital of Shandong UniversityJinan, Shandong18
Yantai Yuhuangding HospitalYantai, Shandong4
The Affiliated Hospital of Qingdao UniversityQingdao, Shandong4

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Qilu Hospital of Shandong University
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06730373First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)Phase IIRECRUITING
NCT06932068Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ AdenocarcinomaPhase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Qilu Hospital of Shandong University Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI